Open Access. Powered by Scholars. Published by Universities.®
D-dimer;; venous thromboembolism;; hospitalization;; enoxaparin;; rivaroxaban;; LIATEST D-DIMER;; MEDICAL PATIENTS;; THROMBOPROPHYLAXIS;; COAGULATION;; RISK;; RIVAROXABAN;; PERFORMANCE;; ENOXAPARIN;; CANCER;; PLASMA;; Hematology;; Peripheral Vascular Disease
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
D-Dimer As A Predictor Of Venous Thromboembolism In Acutely Ill, Hospitalized Patients: A Subanalysis Of The Randomized Controlled Magellan Trial, A. T. Cohen, T. E. Spiro, A. C. Spyropoulos, Y. H. Desanctis, M. Homering, H. R. Buller, L. Haskell, D. Hu, R. Hull, P. Burton, +4 Additional Authors
D-Dimer As A Predictor Of Venous Thromboembolism In Acutely Ill, Hospitalized Patients: A Subanalysis Of The Randomized Controlled Magellan Trial, A. T. Cohen, T. E. Spiro, A. C. Spyropoulos, Y. H. Desanctis, M. Homering, H. R. Buller, L. Haskell, D. Hu, R. Hull, P. Burton, +4 Additional Authors
Journal Articles
Background D-dimer concentrations have not been evaluated extensively as a predictor of increased venous thromboembolism (VTE) risk in acutely ill, hospitalized medical patients. Objectives To analyze the relationships between D-dimer concentration, VTE and bleeding in the MAGELLAN trial (NCT00571649). Patients/methods This was a multicenter, randomized, controlled trial. Patients aged >= 40years, hospitalized for acute medical illnesses with risk factors for VTE received subcutaneous enoxaparin 40mg once daily for 10 +/- 4days then placebo up to day 35, or oral rivaroxaban 10mg once daily for 35 +/- 4days. Patients (n=7581) were grouped by baseline D-dimer2xthe upper limit of normal. VTE and …